Cargando…

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran

PURPOSE: Pseudomonas aeruginosa causes complicated and/or nosocomial UTI. These infections are usually associated with severe and multi-drug resistant P. aeruginosa isolates. As there is no study about the activity of novel antibiotics ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahimzadeh, Mohammad, Habibi, Mehri, Bouzari, Saeid, Asadi Karam, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034959/
https://www.ncbi.nlm.nih.gov/pubmed/32110063
http://dx.doi.org/10.2147/IDR.S243301
_version_ 1783499975000326144
author Rahimzadeh, Mohammad
Habibi, Mehri
Bouzari, Saeid
Asadi Karam, Mohammad Reza
author_facet Rahimzadeh, Mohammad
Habibi, Mehri
Bouzari, Saeid
Asadi Karam, Mohammad Reza
author_sort Rahimzadeh, Mohammad
collection PubMed
description PURPOSE: Pseudomonas aeruginosa causes complicated and/or nosocomial UTI. These infections are usually associated with severe and multi-drug resistant P. aeruginosa isolates. As there is no study about the activity of novel antibiotics ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) against P. aeruginosa isolates in Iran, we aimed to evaluate for the first time the efficacy of these agents against P. aeruginosa isolated from patients with UTI in Iran. Then, the genetic diversity of the resistant isolates was assayed. METHODS: In this study, a total of 200 P. aeruginosa isolates were collected from patients with UTI in Tehran, Iran. Disk diffusion and Minimum Inhibitory Concentration (MIC) methods were applied to determine the resistance of the isolates to CZA, C/T, and the other antibiotics. Extended-spectrum β-lactamases (ESBLs) and Metallo Beta Lactamase (MBL) production were assayed by Combination disk diffusion test (CDDT). Polymerase chain reaction (PCR) was carried out to detect the resistance genes, including beta-lactamases and carbapenemases genes. Finally, genomic analysis of the isolates was performed using the Pulse field gel electrophoresis (PFGE). RESULTS: Among the isolates, 16 (8%) were resistant to CZA and C/T that MIC confirmed it. The resistant isolates showed high resistance to the other classes of antibiotics. Among the resistant isolates, 31.2% and 75% were ESBL and MBL producers, respectively. The prevalence of bla(OXA10), bla(VIM), bla(OXA48), bla(OXA2), and bla(CTX-M) was 100%, 50%, 31.2%, 25%, and 12.5%. Furthermore, two isolates (12.5%) harbored bla(PER) and bla(NDM) genes. The resistant isolates were grouped into 14 distinct pulsotypes and two shared pulsotypes were found. CONCLUSION: Ceftazidime-avibactam and ceftolozane-tazobactam showed high activity against the P. aeruginosa isolated from patients with UTI in Iran. The low rate of resistance to the antibiotics is also alarming and should be considered to avoid further spreading of the antibiotic resistance among the P. aeruginosa and the other bacteria.
format Online
Article
Text
id pubmed-7034959
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70349592020-02-27 First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran Rahimzadeh, Mohammad Habibi, Mehri Bouzari, Saeid Asadi Karam, Mohammad Reza Infect Drug Resist Original Research PURPOSE: Pseudomonas aeruginosa causes complicated and/or nosocomial UTI. These infections are usually associated with severe and multi-drug resistant P. aeruginosa isolates. As there is no study about the activity of novel antibiotics ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) against P. aeruginosa isolates in Iran, we aimed to evaluate for the first time the efficacy of these agents against P. aeruginosa isolated from patients with UTI in Iran. Then, the genetic diversity of the resistant isolates was assayed. METHODS: In this study, a total of 200 P. aeruginosa isolates were collected from patients with UTI in Tehran, Iran. Disk diffusion and Minimum Inhibitory Concentration (MIC) methods were applied to determine the resistance of the isolates to CZA, C/T, and the other antibiotics. Extended-spectrum β-lactamases (ESBLs) and Metallo Beta Lactamase (MBL) production were assayed by Combination disk diffusion test (CDDT). Polymerase chain reaction (PCR) was carried out to detect the resistance genes, including beta-lactamases and carbapenemases genes. Finally, genomic analysis of the isolates was performed using the Pulse field gel electrophoresis (PFGE). RESULTS: Among the isolates, 16 (8%) were resistant to CZA and C/T that MIC confirmed it. The resistant isolates showed high resistance to the other classes of antibiotics. Among the resistant isolates, 31.2% and 75% were ESBL and MBL producers, respectively. The prevalence of bla(OXA10), bla(VIM), bla(OXA48), bla(OXA2), and bla(CTX-M) was 100%, 50%, 31.2%, 25%, and 12.5%. Furthermore, two isolates (12.5%) harbored bla(PER) and bla(NDM) genes. The resistant isolates were grouped into 14 distinct pulsotypes and two shared pulsotypes were found. CONCLUSION: Ceftazidime-avibactam and ceftolozane-tazobactam showed high activity against the P. aeruginosa isolated from patients with UTI in Iran. The low rate of resistance to the antibiotics is also alarming and should be considered to avoid further spreading of the antibiotic resistance among the P. aeruginosa and the other bacteria. Dove 2020-02-17 /pmc/articles/PMC7034959/ /pubmed/32110063 http://dx.doi.org/10.2147/IDR.S243301 Text en © 2020 Rahimzadeh et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Rahimzadeh, Mohammad
Habibi, Mehri
Bouzari, Saeid
Asadi Karam, Mohammad Reza
First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title_full First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title_fullStr First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title_full_unstemmed First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title_short First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
title_sort first study of antimicrobial activity of ceftazidime-avibactam and ceftolozane-tazobactam against pseudomonas aeruginosa isolated from patients with urinary tract infection in tehran, iran
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034959/
https://www.ncbi.nlm.nih.gov/pubmed/32110063
http://dx.doi.org/10.2147/IDR.S243301
work_keys_str_mv AT rahimzadehmohammad firststudyofantimicrobialactivityofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaisolatedfrompatientswithurinarytractinfectionintehraniran
AT habibimehri firststudyofantimicrobialactivityofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaisolatedfrompatientswithurinarytractinfectionintehraniran
AT bouzarisaeid firststudyofantimicrobialactivityofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaisolatedfrompatientswithurinarytractinfectionintehraniran
AT asadikarammohammadreza firststudyofantimicrobialactivityofceftazidimeavibactamandceftolozanetazobactamagainstpseudomonasaeruginosaisolatedfrompatientswithurinarytractinfectionintehraniran